209 related articles for article (PubMed ID: 37714666)
1. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies.
Aureal M; Seauve M; Laplane S; Lega JC; Cabrera N; Coury F
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37714666
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
4. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
6. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.
Machado PM; Schäfer M; Mahil SK; Liew J; Gossec L; Dand N; Pfeil A; Strangfeld A; Regierer AC; Fautrel B; Alonso CG; Saad CGS; Griffiths CEM; Lomater C; Miceli-Richard C; Wendling D; Alpizar Rodriguez D; Wiek D; Mateus EF; Sirotich E; Soriano ER; Ribeiro FM; Omura F; Rajão Martins F; Santos H; Dau J; Barker JN; Hausmann J; Hyrich KL; Gensler L; Silva L; Jacobsohn L; Carmona L; Pinheiro MM; Zelaya MD; Severina MLÁ; Yates M; Dubreuil M; Gore-Massy M; Romeo N; Haroon N; Sufka P; Grainger R; Hasseli R; Lawson-Tovey S; Bhana S; Pham T; Olofsson T; Bautista-Molano W; Wallace ZS; Yiu ZZN; Yazdany J; Robinson PC; Smith CH
Ann Rheum Dis; 2023 May; 82(5):698-709. PubMed ID: 36787993
[TBL] [Abstract][Full Text] [Related]
7. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
9. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
10. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
11. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
12. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
[TBL] [Abstract][Full Text] [Related]
13. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
Michielsens CA; den Broeder N; van den Hoogen FH; Mahler EA; Teerenstra S; van der Heijde D; Verhoef LM; den Broeder AA
Ann Rheum Dis; 2022 Oct; 81(10):1392-1399. PubMed ID: 35701155
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
Ciurea A; Götschi A; Kissling S; Bernatschek A; Bürki K; Exer P; Nissen MJ; Möller B; Scherer A; Micheroli R
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37277211
[TBL] [Abstract][Full Text] [Related]
16. Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis.
Frede N; Rieger E; Lorenzetti R; Nieters A; Venhoff AC; Hentze C; von Deimling M; Bartholomä N; Thiel J; Voll RE; Venhoff N
Front Immunol; 2022; 13():1040725. PubMed ID: 36389682
[TBL] [Abstract][Full Text] [Related]
17. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
[TBL] [Abstract][Full Text] [Related]
18. Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis - data from the Danish nationwide DANBIO registry.
Mathew AJ; Glintborg B; Krogh NS; Hetland ML; Østergaard M
Semin Arthritis Rheum; 2022 Feb; 52():151948. PubMed ID: 35027245
[TBL] [Abstract][Full Text] [Related]
19. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA.
Regierer AC; Weiß A; Proft F; Baraliakos X; Behrens F; Poddubnyy D; Schett G; Lorenz HM; Worsch M; Strangfeld A
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36898762
[TBL] [Abstract][Full Text] [Related]
20. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
